Financial Data and Key Metrics Changes - The company reported net revenues of $16.4 million for Q3 2024, representing over a 120% sequential quarter-over-quarter increase [36] - Gross profit for the quarter was $14 million, equating to a gross margin of 86%, an increase of about 440 basis points over the previous quarter [38] - The company ended the quarter with cash and cash equivalents of $335 million, bolstered by a $130 million equity financing [43][44] Business Line Data and Key Metrics Changes - VOQUEZNA achieved over 143,000 prescriptions filled since launch, with approximately 69,000 filled prescriptions recorded in Q3, nearly doubling the amount from Q2 [25][36] - The number of physicians writing filled prescriptions increased to over 13,600, up from over 8,200 in the previous report, indicating strong adoption [27] - The 10 mg dose for non-Erosive GERD saw an increase in filled prescriptions by over 230% between Q2 and Q3 [25] Market Data and Key Metrics Changes - VOQUEZNA's commercial access now covers over 120 million lives, or more than 80% of all U.S. commercial lives [30] - The company secured FDA approval for VOQUEZNA as a treatment for non-Erosive GERD, significantly expanding its addressable market to roughly 22 million U.S. adults [11] Company Strategy and Development Direction - The company aims to enhance brand awareness and commercial access for VOQUEZNA, focusing on primary care physicians as a key prescriber group [31][82] - The strategy includes expanding direct-to-consumer campaigns to increase patient awareness and drive prescriptions [33][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a blockbuster opportunity with VOQUEZNA, citing strong market interest and positive feedback from physicians and patients [22][23] - The company plans to continue monitoring trends and evaluating data before providing future revenue guidance [77][86] Other Important Information - The company reported a non-GAAP adjusted net loss of $67.9 million for Q3 2024, an improvement from a loss of $73.3 million in Q2 [41] - The company is in the final stages of obtaining FDA alignment for a Phase 2 program investigating VOQUEZNA as a potential treatment for Eosinophilic Esophagitis, planned to initiate in the first half of 2025 [20] Q&A Session Summary Question: Coverage uptake and prescription increase - Management indicated that the growth in prescriptions is a mix of increased access and demand tied to the non-Erosive GERD launch [52] Question: Duration of prescriptions - Most prescriptions are written for 30 days, with some for 60 or 90 days, depending on health plans [55] Question: Gross to net discount expectations - The company expects to remain within the pre-launch discount range of 50% to 65% [62] Question: Regulatory exclusivity for VOQUEZNA - Management confirmed that the exclusivity for VOQUEZNA should protect it from generic entries until 2032 [64] Question: Refill rates and comparison to PPIs - Refill rates are healthy and consistent with expectations for prescription PPIs, indicating a positive trend [68] Question: Primary care awareness and demand - Awareness among primary care physicians is growing, and new prescribers from this group have overtaken gastroenterologists [82] Question: Guidance for 2025 - The company will monitor trends before providing guidance for 2025, ensuring confidence in any projections made [86]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 82-4151574 (State or other juris ...

Financial Performance - Net revenues for Q3 2024 were $16.4 million, a sequential increase of over 120% from $7.3 million in Q2 2024[1] - Product revenue for the three months ended September 30, 2024, was $16,352,000, compared to $0 for the same period in 2023[16] - Gross profit for the nine months ended September 30, 2024, was $21,430,000, reflecting a decrease from $36,505,000 in the same period of 2023[16] - Total operating expenses for the three months ended September 30, 2024, were $84,792,000, up from $35,659,000 in the same period of 2023, representing a 137% increase[16] - Net loss for Q3 2024 was $85.6 million, compared to $43.2 million in Q3 2023, with a non-GAAP adjusted net loss of $67.9 million[7] - Net loss for the three months ended September 30, 2024, was $85,577,000, compared to a net loss of $43,243,000 for the same period in 2023[16] - Non-GAAP adjusted net loss for the three months ended September 30, 2024, was $67,850,000, compared to $30,846,000 for the same period in 2023[17] - Net loss per share, basic and diluted, for the three months ended September 30, 2024, was $(1.32), compared to $(0.76) for the same period in 2023[16] Expenses - R&D expenses decreased to $8.7 million in Q3 2024, down from $12.3 million in Q3 2023, due to lower clinical trial costs[6] - SG&A expenses increased to $76.1 million in Q3 2024, up from $23.4 million in Q3 2023, driven by higher personnel costs and marketing activities[6] - Stock-based compensation expense for the three months ended September 30, 2024, was $5,635,000, compared to $6,140,000 for the same period in 2023[17] - Interest expense for the three months ended September 30, 2024, was $18,484,000, an increase from $10,107,000 in the same period of 2023[16] Market and Product Development - Over 143,000 prescriptions for VOQUEZNA products have been filled, representing a 138% increase since the last quarterly report[3] - Commercial access for VOQUEZNA now covers over 120 million U.S. commercial lives, which is over 80% of the U.S. commercial market[4] - The number of VOQUEZNA prescribers grew to over 13,600, an increase of over 65% from the previous quarter[3] - The recent approval for Non-Erosive GERD has expanded the market opportunity for VOQUEZNA significantly[2] - Phathom plans to initiate a Phase 2 study for Eosinophilic Esophagitis in the first half of 2025[5] Cash Position - Cash and cash equivalents as of September 30, 2024, were $334.7 million, with an additional $125 million available under the term loan[7] Share Information - Weighted-average shares of common stock outstanding, basic and diluted, were 64,627,847 for the three months ended September 30, 2024[18]

Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3] - Vonoprazan is marketed in the U.S. as VOQUEZNA® for treating heartburn associated with Non-Erosive GERD and for healing Erosive GERD in adults [3] Upcoming Events - The company will host a live webcast on November 7, 2024, at 8:30 am ET to report its third quarter 2024 financial results and provide a business update [1] - Additional information and access to the webcast can be found on the Events & Presentations section of the Phathom website [2] - A recording of the webcast will be available for 90 days following the meeting [2]

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA ...

FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold at a price ...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Cau ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 82-4151574 (State or other jurisdicti ...

Company Performance - Phathom Pharmaceuticals reported a quarterly loss of $1.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.20, and compared to a loss of $0.84 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $7.32 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 29.72%, compared to zero revenues a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times [2] Stock Movement and Outlook - Phathom Pharmaceuticals shares have increased by approximately 18.4% since the beginning of the year, outperforming the S&P 500's gain of 9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$1.30 on revenues of $10.94 million, and for the current fiscal year, it is -$4.80 on revenues of $40.48 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Phathom Pharmaceuticals belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5]

Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly report • Net revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increase • VOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non ...